QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers.

HLB combo rivoceranib–camrelizumab extends survival in high-risk liver cancer patients Elevar Therapeutics to present phase 3 ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

Resection of liver metastases is considered the only treatment with curative potential for patients with metastatic colorectal cancer to the liver (CRLM). However, only a minority of patients with ...